Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) has filed a shelf registration statement on Form S-3 to register 470,589 existing common shares for potential resale by its principal venture investor, Sofinnova Venture Partners XI. The shares were originally issued in a $8 million private placement completed on 6 June 2024 at the IPO price of $17.00 per share. Because the shares are already outstanding, the filing does not create dilution; however, it enables Sofinnova (currently 5.1 % owner) to sell down to 3.8 % if the full allotment is distributed.
The company will receive no proceeds from any sale; it is covering an estimated $80 000 in registration expenses, while the selling shareholder will bear brokerage commissions. Following effectiveness, shares may be sold on Nasdaq, in block or negotiated trades, or via Rule 144.
Rapport is a clinical-stage biotech that applies its receptor-associated-protein (RAP) platform to neurological and psychiatric disorders. Lead asset RAP-219—an AMPA receptor negative allosteric modulator targeting TARPγ8—has completed four Phase 1 studies and is in a Phase 2a proof-of-concept trial for refractory focal epilepsy with topline data expected Q3 2025. Additional Phase 2a studies in bipolar mania (Q3 2025 start) and diabetic peripheral neuropathic pain (IND on hold) are planned. Discovery programs in α6 and α9α10 nicotinic acetylcholine receptors address chronic pain and hearing disorders. As an emerging growth and smaller reporting company, Rapport utilizes reduced SEC reporting requirements.
Overall, the filing is largely administrative, aimed at increasing float and fulfilling contractual obligations, with minimal direct financial impact on Rapport’s operations or cash runway.
Rapport Therapeutics (Nasdaq: RAPP) has filed a Form S-3 shelf registration allowing it to issue up to $400 million of common stock, preferred stock, debt, warrants and/or units. The shelf also contains an at-the-market (ATM) facility that permits the company, through Leerink Partners and Cantor Fitzgerald, to sell up to $150 million of common shares from time to time. Any unsold ATM capacity rolls into the broader $400 million shelf authorization.
The filing provides maximum capital flexibility; securities can be offered in multiple tranches, sizes and structures, enabling management to match financing to clinical milestones or market windows. Proceeds are earmarked for general corporate purposes, including R&D and working capital, but no specific timeline or tranche schedule is set—management retains broad discretion over timing and structure. As of June 27 2025, the stock closed at $11.43 and the company had 36.5 million shares outstanding; full use of the shelf (particularly the ATM) could therefore be meaningfully dilutive.
Rapport is an emerging growth and smaller reporting company, affording reduced disclosure and SOX compliance obligations. Its lead candidate, RAP-219, is in a Phase 2a trial for refractory focal epilepsy with top-line data expected Q3 2025; the program also faces an FDA clinical hold for diabetic peripheral neuropathic pain. Two discovery-stage nicotinic receptor programs are in pre-clinical development. Continued clinical progress will determine the pace at which capital is required.
Key investor considerations:
- The shelf signals an intention to raise substantial funds over the next three years, reflecting the high burn typical of clinical-stage biotech.
- The ATM component allows low-friction, opportunistic issuance but can create steady selling pressure.
- The company’s early-stage pipeline means value inflection is tied to clinical readouts; financing risk and execution risk coexist.
Overall, the filing strengthens liquidity options but introduces potential dilution; investors should monitor issuance cadence against trial progress and cash burn.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) filed a Form 8-K to report the voting results of its 2025 Annual Meeting of Stockholders held on June 17 2025. Of the 36,497,555 shares outstanding on the record date, a quorum was present.
Proposal 1 – Election of three Class I directors (terms expiring 2028)
- Reid Huber, Ph.D.: 31,146,580 for, 776,312 withheld, 1,016,695 broker non-votes
- John Maraganore, Ph.D.: 31,222,571 for, 700,321 withheld, 1,016,695 broker non-votes
- Wendy B. Young, Ph.D.: 31,783,990 for, 138,902 withheld, 1,016,695 broker non-votes
All nominees received a clear majority of votes cast and were duly elected.
Proposal 2 – Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2025
- 32,804,657 for, 112,489 against, 22,441 abstain
The appointment of PwC was ratified by 99.4 % of votes cast.
No additional matters were brought to a vote. The filing is routine in nature, dealing solely with corporate governance decisions without disclosing any operational or financial performance data.
Form 4 Overview: Rapport Therapeutics (RAPP) reported an insider transaction for director Ramiro Sanchez on 17 June 2025.
- Type of security: Non-qualified stock option (right to buy).
- Quantity: 10,925 options granted.
- Exercise price: $10.95 per share.
- Vesting: Options vest on the earlier of 17 June 2026 or the date of the next annual meeting, contingent on continued board service.
- Expiration: 17 June 2035.
- Ownership impact: Following the grant, the director now beneficially owns 10,925 derivative securities; no common shares were bought or sold.
The filing indicates a routine equity incentive award to a board member, with no immediate cash outlay or sale of shares. The transaction does not alter the company’s share count or indicate changes in strategic direction but modestly aligns the director’s compensation with long-term shareholder value.
Rapport Therapeutics, Inc. (RAPP) – Form 4 filing
Director Wendy B. Young reported the grant of 10,925 stock options on 17 June 2025 at an exercise price of $10.95. No common shares were bought or sold. The options vest on the earlier of 17 June 2026 or the company’s next annual meeting, contingent on her continued board service, and expire on 17 June 2035. Following the grant, Young beneficially owns 10,925 derivative securities; there is no change to her direct common-stock holdings.
This appears to be a routine equity-incentive award meant to align the director’s interests with shareholders, with no immediate cash impact or dilution event disclosed.
Form 4 Overview – Rapport Therapeutics (RAPP)
- Reporting person: Director John Maraganore.
- Transaction date: 06/17/2025.
- Security: Stock Option (right to buy common shares).
- Quantity granted: 21,850 options.
- Exercise price: $10.95 per share.
- Expiration: 06/17/2035.
- Vesting: Earliest of 06/17/2026 or the next annual shareholder meeting, contingent on continued board service.
- Post-transaction holdings: 21,850 derivative securities; no change reported in directly held common shares.
The filing details a routine director compensation grant rather than an open-market purchase or sale. No shares were disposed of, and the grant does not immediately affect cash flow. Potential dilution is minor—approximately 21.9 k shares—well below thresholds likely to influence valuation for most development-stage biotechs. Because the option strike price sits at $10.95, any future value to the director (and any dilution to existing investors) materialises only if RAPP’s share price exceeds that level. Overall, the disclosure neither signals bullish insider sentiment nor raises governance concerns; it simply aligns the director’s incentives with long-term shareholder value.
Director James Healy of Rapport Therapeutics (RAPP) received a stock option grant for 21,850 shares of common stock on June 17, 2025. The options were granted with the following key terms:
- Exercise price set at $10.95 per share
- Expiration date of June 17, 2035
- Vesting occurs at earlier of June 17, 2026 or next Annual Meeting of Stockholders
- Vesting conditional on continued service as director
The transaction was reported via Form 4 filing and executed under standard compensation arrangements for non-employee directors. The filing was signed by Troy Ignelzi as attorney-in-fact on June 18, 2025. This equity grant aligns the director's interests with shareholders through long-term stock ownership potential.